EGRX - Eagle Pharmaceuticals, Inc.
| Previous Close | 47.15 |
| Open | 47.21 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 900 |
| Day's Range | 46.66 - 48.89 |
| 52 Week Range | 36.03 - 85.66 |
| Volume | 99,826 |
| Avg. Volume | 204,670 |
| Market Cap | 674.215M |
| Beta (3Y Monthly) | 1.53 |
| PE Ratio (TTM) | 23.17 |
| EPS (TTM) | 2.09 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.50 |
- Markit•14 days ago
See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRXView full report here! Summary * Bearish sentiment is moderate Bearish sentimentShort interest | NeutralShort interest is moderately high for EGRX with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold EGRX had net inflows of $1.15 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Thomson Reuters StreetEvents•19 days ago
Edited Transcript of EGRX earnings conference call or presentation 28-Feb-19 1:30pm GMT
Q4 2018 Eagle Pharmaceuticals Inc Earnings Call
Motley Fool•26 days agoEagle Pharmaceuticals Inc (EGRX) Q4 2018 Earnings Conference Call Transcript
EGRX earnings call for the period ending December 31, 2018.
- Business Wire•26 days ago
Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results
-- Q4 2018 net income was $0.88 per basic and $0.86 per diluted share and adjusted non-GAAP net income was $1.23 per basic and $1.20 per diluted share --
- ACCESSWIRE•26 days ago
Eagle Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 ...
- Simply Wall St.•last month
Is Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) ROE Of 15% Impressive?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While some investors are already well versed in financial metricsRead More...
- Zacks•last month
Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•last month
Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2018 fourth quarter and full year financial results on Thursday, February 28, 2019, before the market opens.
- Zacks•last month
Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•last month
Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Simply Wall St.•3 months ago
Does Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) CEO Pay Matter?
Scott Tarriff became the CEO of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in 2007. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
- Business Wire•3 months ago
Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 37th Annual J.P.
- Insider Monkey•3 months ago
Hedge Funds Are Selling Eagle Pharmaceuticals Inc (EGRX)
Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- GlobeNewswire•4 months ago
Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•4 months ago
Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced positive results of a proof-of-concept (POC) study in a Total-Body Radiation Animal Model. The objective of the study was to evaluate the efficacy of intravenous administration of RYANODEX® to prevent or mitigate Acute Radiation Syndrome (ARS) in a total body irradiated C57BL/6 male mouse hematopoietic model.
- Simply Wall St.•4 months ago
Investors Are Undervaluing Eagle Pharmaceuticals Inc (NASDAQ:EGRX) By 28.8%
Does the November share price for Eagle Pharmaceuticals Inc (NASDAQ:EGRX) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by estimating the company’s future cash flows and Read More...
- Business Wire•4 months ago
Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pre
- Zacks•4 months ago
Moving Average Crossover Alert: Eagle Pharmaceuticals (EGRX)
Eagle Pharmaceuticals (EGRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
